GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alpha Teknova Inc (NAS:TKNO) » Definitions » COGS-to-Revenue

Alpha Teknova (Alpha Teknova) COGS-to-Revenue : 0.76 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alpha Teknova COGS-to-Revenue?

Alpha Teknova's Cost of Goods Sold for the three months ended in Mar. 2024 was $7.08 Mil. Its Revenue for the three months ended in Mar. 2024 was $9.29 Mil.

Alpha Teknova's COGS to Revenue for the three months ended in Mar. 2024 was 0.76.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Alpha Teknova's Gross Margin % for the three months ended in Mar. 2024 was 23.78%.


Alpha Teknova COGS-to-Revenue Historical Data

The historical data trend for Alpha Teknova's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alpha Teknova COGS-to-Revenue Chart

Alpha Teknova Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.57 0.43 0.52 0.58 0.72

Alpha Teknova Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.73 0.56 0.82 0.83 0.76

Alpha Teknova COGS-to-Revenue Calculation

Alpha Teknova's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=26.388 / 36.684
=0.72

Alpha Teknova's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=7.081 / 9.29
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alpha Teknova  (NAS:TKNO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Alpha Teknova's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 7.081 / 9.29
=23.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Alpha Teknova COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alpha Teknova's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alpha Teknova (Alpha Teknova) Business Description

Traded in Other Exchanges
N/A
Address
2451 Bert Drive, Hollister, CA, USA, 95023
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification.
Executives
Ken Gelhaus officer: Chief Commercial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Stephen Gunstream director, officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
J Matthew Mackowski director 343 SANSOME ST, SUITE 1215, SANSASAN FRANCISCO CA 94104
Matthew Lowell officer: Chief Financial Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Damon Terrill officer: See Remarks 2290 BERT DRIVE, HOLLISTER CA 95023
Thp Iv Affiliates Fund, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Lisa Hood officer: Chief People Officer 2290 BERT DRIVE, HOLLISTER CA 95023
Irene Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Ted Davis director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Iv, L.p. 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO MA 94108
Paul David Grossman director 1600 FARADAY AVENUE, CARLSBAD CA 92008
Brett Robertson director C/O INVUITY, INC., 444 DE HARO STREET, SAN FRANCOSCO CA 94107
Alexander C. Herzick director 2290 BERT DRIVE, HOLLISTER CA 95023
Telegraph Hill Partners Management Company, Llc 10 percent owner 360 POST STREET, SUITE 601, SAN FRANCISCO CA 94108

Alpha Teknova (Alpha Teknova) Headlines

From GuruFocus

Teknova to Participate in Upcoming Investor Conference

By GuruFocusNews GuruFocusNews 06-04-2022

Teknova to Participate in Upcoming Investor Conferences

By Value_Insider Value_Insider 11-03-2022

Teknova to Participate in Upcoming Investor Conference

By GuruFocusNews GuruFocusNews 06-24-2022

Teknova to Participate in Upcoming Investor Conference

By GuruFocusNews GuruFocusNews 06-14-2022

Teknova to Participate in Upcoming Investor Conference

By GuruFocusNews GuruFocusNews 07-04-2022

Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

By GlobeNewswire GlobeNewswire 05-04-2022